OV05 - A randomised trial in relapsed ovarian cancer: early treatment based on CA125 levels alone vs delayed treatment based on conventional clinical indicators.
First results of the MRC OV05/EORTC 55955 randomised trial were presented by Gordon Rustin at the plenary session at the American Society of Clinical Oncology (ASCO) 2009 Annual Meeting in June. Results have subsequently be presented at the presidential session of the joint European Cancer Organisation (ECCO) and European Society of Medical Oncologists (ESMO) meeting by Maria van der Burg, and by Gordon Rustin at the European Society for Gynaecological Oncology (ESGO) and National Cancer Research Institute (NCRI) meetings.
The first patient was registered in May 1996. These results show no evidence of a benefit from starting chemotherapy for relapsed ovarian cancer earlier (based on doubling of the blood marker CA125) compared to starting chemotherapy when signs or symptoms of tumour recurrence develop. The peer review publication will follow later in 2009.